Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Clinical trial NCT06099990 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06099990
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Start date: 2023-10-01
Primary completion: 2028-12-01
Enrollment: 660

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.